Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Daiichi Sankyo
Farmers Insurance
Harvard Business School
McKesson

Generated: July 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT01606007 Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of this treatment will also be studied.
NCT01619059 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
NCT01646320 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed AstraZeneca Phase 3 The purpose of this study is to learn if BMS-512148 (Dapagliflozin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
NCT02284893 Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Contro Completed AstraZeneca Phase 3 A combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in reducing mean HbA1c over a treatment period of 26 weeks.
NCT02304081 Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function Completed Prof. Dr. Thomas Forst Phase 4 The purpose of this study is to evaluate alpha- and beta-cell function during combination treatment with saxagliptin in addition to dapagliflozin and metformin compared to placebo in addition to dapagliflozin and metformin in subjects with T2DM on stable metformin background therapy.
NCT02419612 A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Cont Active, not recruiting AstraZeneca Phase 3 This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the addition of glimepiride to metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on Metformin Alone. We will compare the change from baseline in HbA1c achieved with saxagliptin, in co-administration with dapagliflozin, added to current background therapy with metformin compared to glimepiride added to current background therapy with metformin ≥1500 mg at Week 52.
NCT02471404 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea Active, not recruiting AstraZeneca Phase 4 This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea) as an addition to metformin treatment.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride

Condition Name

Condition Name for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Intervention Trials
Type 2 Diabetes Mellitus 5
Diabetes Mellitus, Type 2 4
Type 2 Diabetes 4
Type2 Diabetes Mellitus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Intervention Trials
Diabetes Mellitus 18
Diabetes Mellitus, Type 2 17
Hypoglycemia 1
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride

Trials by Country

Trials by Country for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Location Trials
United States 117
Canada 17
Mexico 15
Poland 7
South Africa 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Location Trials
Texas 9
Florida 7
California 7
Arizona 6
South Carolina 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Clinical Trial Phase Trials
Phase 4 4
Phase 3 10
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 6
Completed 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride

Sponsor Name

Sponsor Name for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Sponsor Trials
AstraZeneca 15
The University of Texas Health Science Center at San Antonio 2
Third Affiliated Hospital, Sun Yat-Sen University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dapagliflozin; Metformin Hydrochloride; Saxagliptin Hydrochloride
Sponsor Trials
Industry 17
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Queensland Health
AstraZeneca
Julphar
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.